GlassScriptPhysician profile
Sudhanshu Jain
NPI 1720287295
$667.28
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $74.61 · 2021: $197.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $173.84 | 2019 | |
| Amgen INC. | $136.70 | 2019-2021 | |
| Alkermes, INC. | $125.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $76.18 | 2019-2021 | |
| Cumberland Pharmaceuticals, INC. | $75.05 | 2019-2020 | |
| Glaxosmithkline, LLC. | $26.65 | 2021 | |
| Akebia Therapeutics INC | $20.82 | 2021 | |
| Vifor Pharma, INC. | $18.70 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.34 | 2021 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sudhanshu Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.